Picton Mahoney Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Picton Mahoney Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-125,000	Closed	-$4.8M	–	530
2023 Q2	$4.8M	Buy	+125,000	New	+$3.21M	0.21%	143
2016 Q2	–	Sell	-7,340	Closed	-$470K	–	365
2016 Q1	$470K	Hold	7,340	–	–	0.03%	204
2015 Q4	$1.03M	Hold	7,340	–	–	0.06%	167
2015 Q3	$711K	Sell	7,340 -1,380	-16%	-$164K	0.04%	181
2015 Q2	$1.32M	Buy	+8,720	New	+$1.44M	0.07%	155

Picton Mahoney Asset Management's KDNY Position: Q3 2023 in Review

Picton Mahoney Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 125,000 shares — an estimated $4.8M sold.

Picton Mahoney Asset Management first reported a position in KDNY in Q2 2015 and held it in 5 quarters. The position peaked at $4.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Picton Mahoney Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 125,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.8M.
Picton Mahoney Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Picton Mahoney Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.8M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2023, filed 6 Nov 2023.